CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM further enhances its portfolio in the Cardiology area

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

SOTALEX®/SOTACOR® (Active Ingredient: Sotalol hydrochloride) is an antiarrhythmic drug with Class II (beta-adrenoreceptor blocking) and Class III (cardiac action potential duration prolongation) actions. It is indicated for the treatment of ventricular and supraventricular arrhythmias in adults. It is unique as it has both beta-blocking and antiarrhythmic properties.

With the acquisition and sustainable integration of numerous products in the past, Cardiology already represents one of the primary therapeutic areas in CHEPLAPHARM’s portfolio.

SOTALEX®/SOTACOR® now further promotes the naturally existing synergies between the Cardiology products and, additionally, strengthens CHEPLAPHARM’s International Footprint primarily in Japan and in selected European countries.

“We are highly delighted to have reached an agreement with Bristol-Myers Squibb about the acquisition of SOTALEX®/SOTACOR®”, said CEO Sebastian F. Braun.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com


Investor Relations topics

Back to top expand_less